{
    "nctId": "NCT01896778",
    "briefTitle": "Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer",
    "officialTitle": "Body Warming to Alter [Thermo] Regulation and the Microenvironment [B-WARM] Therapy: A Pilot Study",
    "overallStatus": "COMPLETED",
    "conditions": "Adult Liver Carcinoma, Breast Carcinoma, Colon Carcinoma, Kidney Neoplasm, Lung Carcinoma, Malignant Head and Neck Neoplasm, Malignant Neoplasm, Melanoma, Ovarian Neoplasm, Soft Tissue Sarcoma",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "BASIC_SCIENCE",
    "enrollmentCount": 9,
    "primaryOutcomeMeasure": "Changes in tumor vascular (blood flow, blood volume)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with a variety of malignancies (i.e., melanoma, sarcoma, colon, head and neck, renal, breast, lung, ovary, liver)\n* Patients must have measurable disease (1.0 cm or greater) by computed tomography (CT) scan\n* Have an estimated glomerular filtration rate (eGFR) (using the Cockcroft-Gault equation) of more than 60 mL/min\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n* Patients of child-bearing potential must agree to use acceptable contraceptive methods (e.g., double barrier) during treatment\n* Patient or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure\n\nExclusion Criteria:\n\n* History of prior myocardial infarction or arrhythmia\n* History of any condition deemed by the principal investigator to be a contraindication to B-WARM therapy (e.g., skin reaction, dysregulation of thermoregulation, etc)\n* All patients with transdermal patches (e.g.; fentanyl, Lidoderm, scopolamine, etc)\n* Pregnant or nursing female patients\n* Unwilling or unable to follow protocol requirements\n* Any condition which in the investigator's opinion deems the patient an unsuitable candidate to receive B-WARM\n* Received an investigational agent within 30 days prior to enrollment\n* Received any systemic therapy within 21 days prior to planned B-WARM therapy\n\n  * Patients may be enrolled on study but at least 21 days should elapse prior to date of B-WARM therapy\n* Patients should not have either CT scanning or B-WARM if they have a fever at the time\n\n  * Fever should be worked up and treated as appropriate\n  * Patients should be afebrile for 24 hours prior to scanning or B-WARM therapy",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}